Literature DB >> 2114945

Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.

M S Baker1, P Bleakley, G C Woodrow, W F Doe.   

Abstract

Isotopically labeled [( 3H]serine, [3H]proline, and [35S]sulfate) subendothelial cell basement membranes were used to determine the role of urokinase plasminogen activator (uPA) and its specific inhibitor plasminogen activator inhibitor 2 (PAI-2) in colon cancer cell extracellular matrix degradation. Recombinant PAI-2 irreversibly inhibited low and high molecular weight purified human uPA in addition to both colon cancer cell-associated and secreted uPA, particularly if pro-uPA had been preactivated. Two selected lines (COLO394 and LIM1215) preferentially degraded differently labeled matrices in a time- and plasminogen-dependent manner. This process was inhibitable by PAI-2 in the medium at levels which suggested that some degree of "shielding" of cell surface uPA from inhibitor occurred. The ability of PAI-2 to regulate the invasive phenotype of cells which express cell surface or receptor-bound uPA is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114945

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2.

Authors:  S S Lakka; S D Konduri; S Mohanam; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 2.  The role of proteolytic enzymes in cancer invasion and metastasis.

Authors:  M J Duffy
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

3.  Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.

Authors:  M R Gyetko; G H Chen; R A McDonald; R Goodman; G B Huffnagle; C C Wilkinson; J A Fuller; G B Toews
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells.

Authors:  T Abe; T Mori; K Kohno; M Seiki; T Hayakawa; H G Welgus; S Hori; M Kuwano
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

5.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

6.  Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.

Authors:  D M Evans; K Sloan-Stakleff; M Arvan; D P Guyton
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

7.  Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion.

Authors:  H Kobayashi; H Shinohara; H Ohi; M Sugimura; T Terao; M Fujie
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

8.  Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney.

Authors:  S N Wagner; M J Atkinson; C Wagner; H Höfler; M Schmitt; O Wilhelm
Journal:  Histochem Cell Biol       Date:  1996-01       Impact factor: 4.304

9.  Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors.

Authors:  J S Rao; A Rayford; R A Morantz; B W Festoff; R Sawaya
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

Review 10.  Adhesion molecules and their role in cancer metastasis.

Authors:  R M Lafrenie; M R Buchanan; F W Orr
Journal:  Cell Biophys       Date:  1993 Aug-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.